CHINA PHARMA HOLDINGS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $214.07 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-11-12
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was -$2.65K.
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $519.00.
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $10.00.
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $156.27K.
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $168.61K, a 26.59% decline from fiscal 2020.
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $229.67K, a 0.01% increase from fiscal 2019.
- CHINA PHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $229.64K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-09-30 | $214.07K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | -$2.65K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$2.65K derived: sum of 2 quarters · filed 2025-03-31 | $156.27K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $158.93K 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $158.93K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $519.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $529.00 derived: sum of 2 quarters · filed 2023-03-30 | $168.61K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $10.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $168.09K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $168.08K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $229.67K 10-K · filed 2022-03-30 | |||
| 2019-12-31 | -$1.49K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | -$3.98K derived: sum of 2 quarters · filed 2021-03-26 | -$6.41K derived: sum of 3 quarters · filed 2021-03-26 | $229.64K 10-K · filed 2021-03-26 |
| 2019-09-30 | -$2.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$4.92K derived: sum of 2 quarters · filed 2020-11-13 | $231.13K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | -$2.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $233.63K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $236.06K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |